The merits of buprenorphine for pregnant women with opioid use disorder
Several medication-assisted treatments (MATs) for opioid use disorder were highlighted in “What clinicians need to know about treating opioid use disorder,” (Evidence-Based Reviews, Current Psychiatry. August 2016 p. 20-24,30-31,34,36,39) namely, methadone, buprenorphine/naloxone, and naltrexone. For treating pregnant women, methadone was the only MAT noted. Although methadone has been the standard treatment for pregnant patients with opioid use disorder for more than 40 years, recently, buprenorphine has become a reasonable alternative.1 In the past, published data on the use of buprenorphine in these patients was limited; in recent years, studies have highlighted use of buprenorphine and its advantages over methadone.
The landmark study, the Maternal Opioid Treatment: Human Experimental Research, a 2010 multicenter randomized controlled trial compared buprenorphine with methadone in pregnant women with opioid use disorder. The results revealed that neonates exposed to buprenorphine needed 89% less morphine to treat neonatal abstinence syndrome (NAS), 43% shorter hospital stay, and 58% shorter duration of medical treatment for NAS compared with those receiving methadone. Other advantages of buprenorphine over methadone are lower risk of overdose, fewer drug–drug interactions, and the option of receiving treatment in an outpatient setting, rather than a licensed treatment program, such as a methadone maintenance treatment program, which is more tightly controlled.1-3
The previous recommendation was to consider buprenorphine for patients who refused methadone or were unable to take it, or when a methadone treatment program wasn’t available. This study highlighted some clear advantages for treating this subpopulation with methadone instead of buprenorphine: only 18% of patients receiving methadone discontinued treatment, compared with 33% of those receiving buprenorphine,1-3 and methadone had a lower risk of diversion.3 The accepted practice has been to recommend methadone treatment for patients with mental, physical, or social stressors because of the structure of opioid treatment programs (OTP) (also known as methadone maintenance treatment programs). However, buprenorphine can be dispensed through an OTP, following the same stringent rules and regulations.4
The single agent, buprenorphine—not buprenorphine/naloxone—is recommended to prevent prenatal exposure to naloxone. It is thought that exposure to naloxone in utero might produce hormonal changes in the fetus.1,5 O'Connor et al5 noted methadone’s suitability during breast-feeding because of its low concentration in breast milk. Buprenorphine is excreted at breast milk to plasma ratio of 1:1, but because of buprenorphine’s poor oral bioavailability, infant exposure has little impact on the NAS score, therefore it’s suitable for breast-feeding mothers.5
Adegboyega Oyemade, MD, FAPA
Addiction Psychiatrist
Kaiser Permanente
Baltimore, Maryland
References
1. Lori W. Buprenorphine during pregnancy reduces neonate distress. https://www.drugabuse.gov/news-events/nida-notes/2012/07/buprenorphine- during-pregnancy-reduces-neonate-distress. Published July 6, 2016. Accessed September 9, 2016.
2. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331.
3. ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obest Gynecol. 2012;119(5):1070-1076.
4. Addiction Treatment Forum. Methadone vs. buprenorphine: how do OTPs and patients make the choice? http://atforum.com/2013/11/methadone-vs-buprenorphine-how-do-otps-and-patients-make-the-choice. Published November 15, 2013. Accessed September 9, 2016.
5. O’Connor A, Alto W, Musgrave K, et al. Observational study of buprenorphine treatment of opioid-dependent pregnancy women in a family medicine residency: reports on maternal and infant outcomes. J Am Board Fam Med. 2011;24(2):194-201.